Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

TSX:AEZS - Post Discussion

COSCIENS Biopharma Inc > Re: Strategic acquisitions
View:
Post by Hopeforthebest on Jul 12, 2024 11:43am

Re: Strategic acquisitions

Of course gagnon would be on the lookout for new acquistions, like the one he did with Juvenite, took a company that had hundred of thousands in sales and ran that down to less than $30,000 in sales per year meanwhile appointing himself as CEO and paying himself at least $250,000 per year. 
That gagnon has a special kind of talent bankrupt anything he touches, devalue shareholder value, increase top heavy management, lie to shareholders (can we say OATS) and still he manages to pay him and his friends mega bucks
Comment by prophetoffactz on Jul 12, 2024 12:25pm
"Of course gagnon would be on the lookout for new acquistions, like the one he did with Juvenite, took a company that had hundred of thousands in sales and ran that down to less than $30,000 in sales per year..." Too funny. You still can't see the real significance of Juvente. Gilles has proven up a number of use-cases for PGX from an immune booster, to a CoQ10 functional drink, to ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities